Does EU and US paediatric legislation improve the authorization availability of medicines for children in other countries?

• Published in: British journal of clinical pharmacology 2023-03, Vol.89 (3), p.1056-1066
• Main Authors: Volodina, Anna, Shah‐Rohlfs, Rupal, Jahn, Albrecht
• Format: Article
• Language: English
• Subjects: access to medicines; age‐appropriate formulations; authorization availability; Child; Drug Compounding; Drug Industry; Drugs, Generic; European Union; Humans; medicines for children; Pharmaceutical Preparations
• ISSN: 0306-5251; 1365-2125
• DOI: 10.1111/bcp.15553

Aim For over 15 years, the pharmaceutical industry has been engaged in developing medicines for children to comply with the European Union (EU) and the United States (US) regulatory requirements. We assessed the authorization availability of these medicines in countries without paediatric regulatory obligations. Special attention was given to the authorization availability of paediatric formulations. Methods Medicines for children were sampled from the US Food and Drug Administration and European Medicines Agency websites. We carried out systematic content analysis of product information and compared paediatric labelling in Australia, Brazil, Canada, Russia and South Africa with the EU or the US. The authorization availability of paediatric formulations in originator and generic medicines was reviewed. In Kenya, the authorization availability of sampled medicines and paediatric formulations was investigated. Results A total of 161 medicines authorized in the EU or the US were sampled. Whilst at least one paediatric indication was found in 70% of the medicines, the EU and US level of authorization was on average 38% in Australia, Brazil, Canada, Russia and South Africa. Paediatric formulations were authorized on average for 40% of originator and 36% of generic medicines. Kenya had the lowest authorization availability of medicines (40%) and formulations (26%). Conclusions The authorization availability of novel medicines for children is lower in countries without paediatric regulatory obligations. Paediatric formulations often do not reach other countries if left unregulated, and their generic uptake is low. To increase authorization availability, submission of paediatric development results should become obligatory in each jurisdiction. Policy initiatives to stimulate the introduction of developed formulations should be encouraged.